Outcomes and hospital admissions during long-term support with a HeartMate II

Scandinavian Cardiovascular Journal

Volumn 49, Issue 6, 2015, Pages 367-375

  Rossing, Kasper ^a   Junge, Mette Holme ^a   Sander, Kaare ^a   Olsen, Peter Skov ^a   Hansen, Peter Bo ^a   Boesgaard, Søren ^a   Gustafsson, Finn ^a  

^a Rigshospitalet   (Denmark)

Author keywords

heart failure; hospital admissions; left ventricular assist device; survival

Indexed keywords

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRIDGE TO TRANSPLANTATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PROCEDURE; COMPARATIVE STUDY; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; CONTROLLED STUDY; DESTINATION THERAPY; DEVICE INFECTION; DIZZINESS; DRIVELINE INFECTION; EVALUATION STUDY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERVOLEMIA; LENGTH OF STAY; LONG TERM CARE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; RETROSPECTIVE STUDY; SURVIVAL; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; AGED; DEVICE REMOVAL; HEART ASSIST DEVICE; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROSTHESIS DESIGN; RISK FACTOR; TIME FACTOR;

ADULT; AGED; DEVICE REMOVAL; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT READMISSION; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84942235753     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2015.1086016     Document Type: Article

References (25)

1. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001; 345: 1435-43.
2. Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. 2003; 9: 180-7.
3. Gorodeski EZ, Chu EC, Reese JR, Shishehbor MH, Hsich E, Starling RC. Prognosis on chronic dobutamine or milrinone infusions for stage Dheart failure. Circ Heart Fail. 2009; 2: 320-4.
4. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009; 361: 2241-51.
5. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007; 357: 885-96.
6. Andersen M, Videbaek R, Boesgaard S, Sander K, Hansen PB, Gustafsson F. Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). J Heart Lung Transplant. 2009; 28: 733-5.
7. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013; 32: 157-87.
8. Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010; 29: S1-39.
9. Lahpor J, Khaghani A, Hetzer R, Pavie A, Friedrich I, Sander K, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2010; 37: 357-61.
10. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant. 2014; 33: 555-64.
11. Hasin T, Marmor Y, Kremers W, Topilsky Y, Severson CJ, Schirger JA, et al. Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol. 2013; 61: 153-63.
12. Forest SJ, Bello R, Friedmann P, Casazza D, Nucci C, Shin JJ, et al. Readmissions after ventricular assist device: etiologies, patterns, and days out of hospital. Ann Thorac Surg. 2013; 95: 1276-81.
13. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, et al. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2009; 119: 969-77.
14. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012; 5: 241-8.
15. Goldstein DJ, Naftel D, Holman W, Bellumkonda L, Pamboukian SV, Pagani FD, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant. 2012; 31: 1151-7.
16. Bomholt T, Moser C, Sander K, Boesgaard S, Kober L, Olsen PS, et al. Driveline infections in patients supported with a HeartMate II: incidence, aetiology and outcome. Scand Cardiovasc J. 2011; 45: 273-8.
17. Slaughter MS. Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res. 2010; 3: 618-24.
18. Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009; 53: 2162-7.
19. Morgan JA, Paone G, Nemeh HW, Henry SE, Patel R, Vavra J, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2012; 31: 715-8.
20. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369: 1206-14.
21. Enriquez AD, Calenda B, Gandhi PU, Nair AP, Anyanwu AC, Pinney SP. Clinical Impact of Atrial Fibrillation in Patients With the HeartMate II Left Ventricular Assist Device. J Am Coll Cardiol. 2014; 64: 1883-90.
22. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. Ameta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009; 11: 676-83.
23. Al-Sarraf N, Thalib L, Hughes A, Tolan M, Young V, McGovern E. Effect of Preoperative Atrial Fibrillation on Postoperative Outcome following Cardiac Surgery. Cardiol Res Pract. 2012; 2012: 272-384.
24. Hottigoudar RU, Deam AG, Birks EJ, McCants KC, Slaughter MS, Gopinathannair R. Catheter ablation of atrial flutter in patients with left ventricular assist device improves symptoms of right heart failure. Congest Heart Fail. 2013; 19: 165-71.
25. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014; 370: 33-40.